Coverage Policies

Use the index below to search for coverage information on specific medical conditions.

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.

High-Tech Imaging: High-Tech Imaging services are administered by National Imaging Associates, Inc. (NIA). For coverage information and authorizations, click here.

Medical Providers: Payment for care or services is based on eligibility, medical necessity and available benefits at time of service and is subject to all contractual exclusions and limitations, including pre-existing conditions if applicable.

Future eligibility cannot be guaranteed and should be rechecked at time of service. Verify benefits by signing into My Account or calling Customer Service at 800.235.7111 or 501.228.7111.

QualChoice follows care guidelines published by MCG Health.

INDEX:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Effective Date: 01/01/2021 Title: Tecartus (brexucabtagene)
Revision Date: Document: BI667:00
CPT Code(s): C9073, Q2053
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Tecartus requires prior authorization.

2)    Tecartus is used to treat Large B-cell Lymphoma.


Medical Statement

Initial Approval Criteria A. Mantle Cell Lymphoma* (must meet all):

 

*Only for initial treatment dose; subsequent doses will not be covered.

1. Diagnosis of relapsed or refractory MCL;

2. Prescribed by or in consultation with an oncologist or hematologist;

3. Age ≥ 18 years;

4. Recent (within the last 30 days) absolute lymphocyte count (ALC) ≥ 100 cells/μL;

5. Member has previously received 2 to 5 prior regimens that included all of the following (a, b, and c): a. Anthracycline (e.g., doxorubicin) or bendamustine-containing chemotherapy;

b. Anti-CD20 monoclonal antibody therapy (e.g., rituximab);

c. Bruton tyrosine kinase (BTK) inhibitor (e.g., Imbruvica®, Calquence®, Brukinsa™);

 

6. Member does not have a history of or current central nervous system (CNS) disease or CNS disorders (i.e., detectable cerebrospinal fluid malignant cells or brain metastases, CNS lymphoma, seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement);

7. Member does not have a history of allogeneic stem cell transplantation;

 

8. Member has not previously received treatment with CAR T-cell immunotherapy (e.g., Kymriah™, Yescarta™);

9. Tecartus is not prescribed concurrently with other CAR T-cell immunotherapy (e.g., Kymriah, Yescarta);

10. Dose does not exceed 2 x 108 CAR-positive viable T cells/kg.

 

Approval duration: 3 months (1 dose only, with 4 doses of tocilizumab (Actemra) at up to 800 mg per dose)

 

Codes Used In This BI:

 

1)    C9073  Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (code deleted & replaced by Q2053 eff 04/01/2021)

2)    Q2053  Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose (new code eff 04/01/2021


Limits
Limited to one dose per lifetime.
Reference

1. Tecartus Prescribing Information. Santa Monica, CA: Kite Pharma, Inc.; July 2020. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf. Accessed July 27, 2020.

2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020;382:1331-42.

3. National Comprehensive Cancer Network. B-cell Lymphomas Version 2.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed July 27, 2020.

 

Addendum:

1)    Effective 01-01-2021: New code C9073.

2)    Effective 04/01/2021: Deleted code C9073 & replaced by Q2053


Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
This policy has recently been updated. Please use the index above or enter policy title in search bar for the latest version.